NATCO Launches Pomalid, First Generic Version Of Pomalidomide Capsules, For Treatment Of A Specific Blood Cancer, In India

Hyderabad, India (Press Release) – Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announced today that it has launched a generic version of pomalidomide 1 mg, 2 mg, and 4 mg capsules in India. Pomalidomide is sold by Celgene Inc., in the USA, under the brand name POMALYST®.
Pomalidomide is a thalidomide analogue indicated, in combination with dexamethasone, for patients with multiple myeloma (a type of blood cancer) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Natco will market generic pomalidomide capsules under its brand name POMALID in India. Natco priced its generic medicine of POMALID 1 mg, 2 mg, and 4 mg capsules at an MRP of INR 5000/-, INR 10,000/-, and INR 20,000/- respectively for a monthly pack of 21 capsules. We believe, this is approximately 98% discount of price from what it is sold at in the USA to patients, per secondary market data researched.
Source: NATCO.
Related Press Releases:
- Breckenridge Announces Final Approval Of Its ANDA For Pomalidomide Capsules (Generic For Pomalyst)
- Janssen Submits Applications In U.S. And EU Seeking Approval of Darzalex Faspro (Daratumumab And Hyaluronidase-fihj) / Darzalex (Daratumumab) Subcutaneous (SC) Formulation In Combination With Pomalidomide And Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma
- Genmab Announces IFM, HOVON And Janssen Achieve Positive Topline Results In Second Part Of Phase 3 CASSIOPEIA Study Of Daratumumab In Multiple Myeloma At Pre-Planned Interim Analysis
- With The Priority Review Underway At FDA, Oncopeptides Moves Forward With Intent To File For Conditional Approval Of Melflufen With EMA
- OncoPep Strengthens Pipeline With Addition Of Multi-Tumor Antigen Adoptive T Cell Therapy